Interim Condensed Consolidated Statements of Changes in Temporary Equity and Shareholders' Deficiency - USD ($)
$ in Thousands |
Common Shares
Class B common shares
|
Common Shares |
Additional paid-in capital |
Accumulated deficit |
Accumulated other comprehensive loss |
Redeemable convertible preferred shares |
Class B common shares |
Total |
| Beginning balance at Dec. 31, 2023 |
|
|
|
|
|
|
|
$ 237,671
|
|
| Beginning balance (in shares) at Dec. 31, 2023 |
|
|
|
|
|
|
|
17,757,257
|
|
| Changes in redeemable convertible preferred stock |
|
|
|
|
|
|
|
|
|
| F1 preferred shares deemed dividend |
|
|
|
|
|
|
|
$ 3,384
|
|
| Ending balance at Dec. 31, 2024 |
|
|
|
|
|
$ 245,121
|
|
$ 245,121
|
[1] |
| Ending balance (in shares) at Dec. 31, 2024 |
|
|
|
|
|
18,082,742
|
|
18,082,742
|
|
| Beginning balance at Dec. 31, 2023 |
|
|
$ 14,706
|
$ (233,346)
|
$ (4,450)
|
|
|
$ (220,726)
|
|
| Changes in shareholders' deficiency |
|
|
|
|
|
|
|
|
|
| Exercise of common share options |
|
|
(39)
|
|
|
|
|
4
|
|
| Share-based compensation (note 16) |
|
|
1,253
|
|
|
|
|
1,253
|
|
| F1 preferred shares deemed dividend |
|
|
|
(3,384)
|
|
|
|
(3,384)
|
|
| Net and comprehensive loss for the period |
|
|
|
(57,770)
|
601
|
|
|
(57,169)
|
|
| Ending balance at Dec. 31, 2024 |
|
$ 2,407
|
15,920
|
(298,566)
|
(3,849)
|
|
|
$ (284,088)
|
|
| Ending balance (in shares) at Dec. 31, 2024 |
|
1,316,702
|
|
|
|
|
0
|
1,316,702
|
|
| Changes in redeemable convertible preferred stock |
|
|
|
|
|
|
|
|
|
| F1 preferred shares deemed dividend |
|
|
|
|
|
$ 1,694
|
|
|
|
| Ending balance at Mar. 31, 2025 |
|
|
|
|
|
$ 246,815
|
|
|
|
| Ending balance (in shares) at Mar. 31, 2025 |
|
|
|
|
|
18,082,742
|
|
|
|
| Changes in shareholders' deficiency |
|
|
|
|
|
|
|
|
|
| Share-based compensation (note 16) |
|
|
285
|
|
|
|
|
$ 285
|
|
| F1 preferred shares deemed dividend |
|
|
|
(1,694)
|
|
|
|
(1,694)
|
|
| Net and comprehensive loss for the period |
|
|
|
(5,688)
|
(623)
|
|
|
(6,311)
|
|
| Ending balance at Mar. 31, 2025 |
|
$ 2,407
|
16,205
|
(305,948)
|
(4,472)
|
|
|
(291,808)
|
|
| Ending balance (in shares) at Mar. 31, 2025 |
|
1,316,702
|
|
|
|
|
|
|
|
| Beginning balance at Dec. 31, 2024 |
|
|
|
|
|
$ 245,121
|
|
$ 245,121
|
[1] |
| Beginning balance (in shares) at Dec. 31, 2024 |
|
|
|
|
|
18,082,742
|
|
18,082,742
|
|
| Ending balance at Jun. 30, 2025 |
|
|
|
|
|
$ 246,815
|
|
|
|
| Ending balance (in shares) at Jun. 30, 2025 |
|
|
|
|
|
18,082,742
|
|
|
|
| Beginning balance at Dec. 31, 2024 |
|
$ 2,407
|
15,920
|
(298,566)
|
(3,849)
|
|
|
$ (284,088)
|
|
| Beginning balance (in shares) at Dec. 31, 2024 |
|
1,316,702
|
|
|
|
|
0
|
1,316,702
|
|
| Changes in shareholders' deficiency |
|
|
|
|
|
|
|
|
|
| Net and comprehensive loss for the period |
|
|
|
|
|
|
|
$ (12,859)
|
|
| Ending balance at Jun. 30, 2025 |
|
$ 2,413
|
16,434
|
(309,971)
|
(6,998)
|
|
|
(298,122)
|
|
| Ending balance (in shares) at Jun. 30, 2025 |
|
1,318,892
|
|
|
|
|
|
|
|
| Beginning balance at Dec. 31, 2024 |
|
|
|
|
|
$ 245,121
|
|
$ 245,121
|
[1] |
| Beginning balance (in shares) at Dec. 31, 2024 |
|
|
|
|
|
18,082,742
|
|
18,082,742
|
|
| Changes in redeemable convertible preferred stock |
|
|
|
|
|
|
|
|
|
| F1 preferred shares deemed dividend |
|
|
|
|
|
|
|
$ 1,694
|
|
| Ending balance at Dec. 31, 2025 |
|
|
|
|
|
$ 122,953
|
|
$ 122,953
|
[1] |
| Ending balance (in shares) at Dec. 31, 2025 |
|
|
|
|
|
189,817,561
|
0
|
189,817,561
|
|
| Beginning balance at Dec. 31, 2024 |
|
$ 2,407
|
15,920
|
(298,566)
|
(3,849)
|
|
|
$ (284,088)
|
|
| Beginning balance (in shares) at Dec. 31, 2024 |
|
1,316,702
|
|
|
|
|
0
|
1,316,702
|
|
| Changes in shareholders' deficiency |
|
|
|
|
|
|
|
|
|
| Exercise of common share options |
|
|
(4)
|
|
|
|
|
$ 4
|
|
| Share-based compensation (note 16) |
|
|
1,345
|
|
|
|
|
1,345
|
|
| F1 preferred shares deemed dividend |
|
|
|
(1,694)
|
|
|
|
(1,694)
|
|
| Net and comprehensive loss for the period |
|
|
|
(31,370)
|
(2,855)
|
|
|
(34,225)
|
|
| Ending balance at Dec. 31, 2025 |
|
$ 146,525
|
18,327
|
(331,952)
|
(6,704)
|
|
|
$ (173,804)
|
|
| Ending balance (in shares) at Dec. 31, 2025 |
|
13,290,803
|
|
|
|
|
0
|
13,290,803
|
|
| Beginning balance at Mar. 31, 2025 |
|
|
|
|
|
$ 246,815
|
|
|
|
| Beginning balance (in shares) at Mar. 31, 2025 |
|
|
|
|
|
18,082,742
|
|
|
|
| Ending balance at Jun. 30, 2025 |
|
|
|
|
|
$ 246,815
|
|
|
|
| Ending balance (in shares) at Jun. 30, 2025 |
|
|
|
|
|
18,082,742
|
|
|
|
| Beginning balance at Mar. 31, 2025 |
|
$ 2,407
|
16,205
|
(305,948)
|
(4,472)
|
|
|
$ (291,808)
|
|
| Beginning balance (in shares) at Mar. 31, 2025 |
|
1,316,702
|
|
|
|
|
|
|
|
| Changes in shareholders' deficiency |
|
|
|
|
|
|
|
|
|
| Exercise of common share options |
|
$ 6
|
(4)
|
|
|
|
|
2
|
|
| Exercise of common share options (in shares) |
|
2,190
|
|
|
|
|
|
|
|
| Share-based compensation (note 16) |
|
|
233
|
|
|
|
|
233
|
|
| Net and comprehensive loss for the period |
|
|
|
(4,022)
|
(2,526)
|
|
|
(6,548)
|
|
| Ending balance at Jun. 30, 2025 |
|
$ 2,413
|
16,434
|
(309,971)
|
(6,998)
|
|
|
(298,122)
|
|
| Ending balance (in shares) at Jun. 30, 2025 |
|
1,318,892
|
|
|
|
|
|
|
|
| Beginning balance at Dec. 31, 2025 |
|
|
|
|
|
$ 122,953
|
|
$ 122,953
|
[1] |
| Beginning balance (in shares) at Dec. 31, 2025 |
|
|
|
|
|
189,817,561
|
0
|
189,817,561
|
|
| Changes in redeemable convertible preferred stock |
|
|
|
|
|
|
|
|
|
| Issuance of common shares |
|
|
|
|
|
|
$ 25,956
|
|
|
| Issuance of common shares (in shares) |
|
|
|
|
|
|
3,500,000
|
|
|
| Ending balance at Jan. 31, 2026 |
|
|
|
|
|
|
$ 26,306
|
|
|
| Beginning balance at Dec. 31, 2025 |
|
$ 146,525
|
18,327
|
(331,952)
|
(6,704)
|
|
|
$ (173,804)
|
|
| Beginning balance (in shares) at Dec. 31, 2025 |
|
13,290,803
|
|
|
|
|
0
|
13,290,803
|
|
| Beginning balance at Dec. 31, 2025 |
|
|
|
|
|
$ 122,953
|
|
$ 122,953
|
[1] |
| Beginning balance (in shares) at Dec. 31, 2025 |
|
|
|
|
|
189,817,561
|
0
|
189,817,561
|
|
| Changes in redeemable convertible preferred stock |
|
|
|
|
|
|
|
|
|
| Issuance of common shares |
|
|
|
|
|
|
$ 26,306
|
|
|
| Issuance of common shares (in shares) |
|
|
|
|
|
|
3,500,000
|
|
|
| Ending balance at Mar. 31, 2026 |
|
|
|
|
|
$ 122,953
|
$ 26,306
|
|
|
| Ending balance (in shares) at Mar. 31, 2026 |
|
|
|
|
|
189,817,561
|
3,500,000
|
|
|
| Beginning balance at Dec. 31, 2025 |
|
$ 146,525
|
18,327
|
(331,952)
|
(6,704)
|
|
|
$ (173,804)
|
|
| Beginning balance (in shares) at Dec. 31, 2025 |
|
13,290,803
|
|
|
|
|
0
|
13,290,803
|
|
| Changes in shareholders' deficiency |
|
|
|
|
|
|
|
|
|
| Exercise of common share options |
|
$ 42
|
(42)
|
|
|
|
|
|
|
| Exercise of common share options (in shares) |
|
15,616
|
|
|
|
|
|
|
|
| Share-based compensation (note 16) |
|
|
105
|
|
|
|
|
$ 105
|
|
| Net and comprehensive loss for the period |
|
|
|
(38,812)
|
886
|
|
|
(37,926)
|
|
| Ending balance at Mar. 31, 2026 |
|
$ 146,567
|
18,390
|
(370,764)
|
(5,818)
|
|
|
(211,625)
|
|
| Ending balance (in shares) at Mar. 31, 2026 |
|
13,306,419
|
|
|
|
|
|
|
|
| Beginning balance at Dec. 31, 2025 |
|
|
|
|
|
$ 122,953
|
|
$ 122,953
|
[1] |
| Beginning balance (in shares) at Dec. 31, 2025 |
|
|
|
|
|
189,817,561
|
0
|
189,817,561
|
|
| Changes in redeemable convertible preferred stock |
|
|
|
|
|
|
|
|
|
| Issuance of common shares |
$ 26,306
|
|
|
|
|
|
|
|
|
| Issuance of common shares (in shares) |
|
|
|
|
|
|
3,500,000
|
|
|
| Ending balance at Jun. 30, 2026 |
|
|
|
|
|
$ 122,953
|
$ 26,306
|
|
|
| Ending balance (in shares) at Jun. 30, 2026 |
|
|
|
|
|
189,817,561
|
3,500,000
|
|
|
| Beginning balance at Dec. 31, 2025 |
|
$ 146,525
|
18,327
|
(331,952)
|
(6,704)
|
|
|
$ (173,804)
|
|
| Beginning balance (in shares) at Dec. 31, 2025 |
|
13,290,803
|
|
|
|
|
0
|
13,290,803
|
|
| Changes in shareholders' deficiency |
|
|
|
|
|
|
|
|
|
| Net and comprehensive loss for the period |
|
|
|
|
|
|
|
$ (119,165)
|
|
| Ending balance at Jun. 30, 2026 |
|
$ 146,609
|
18,586
|
(454,456)
|
(3,365)
|
|
|
$ (292,626)
|
|
| Ending balance (in shares) at Jun. 30, 2026 |
|
13,324,608
|
|
|
|
|
|
13,324,608
|
|
| Beginning balance at Mar. 31, 2026 |
|
|
|
|
|
$ 122,953
|
$ 26,306
|
|
|
| Beginning balance (in shares) at Mar. 31, 2026 |
|
|
|
|
|
189,817,561
|
3,500,000
|
|
|
| Ending balance at Jun. 30, 2026 |
|
|
|
|
|
$ 122,953
|
$ 26,306
|
|
|
| Ending balance (in shares) at Jun. 30, 2026 |
|
|
|
|
|
189,817,561
|
3,500,000
|
|
|
| Beginning balance at Mar. 31, 2026 |
|
$ 146,567
|
18,390
|
(370,764)
|
(5,818)
|
|
|
$ (211,625)
|
|
| Beginning balance (in shares) at Mar. 31, 2026 |
|
13,306,419
|
|
|
|
|
|
|
|
| Changes in shareholders' deficiency |
|
|
|
|
|
|
|
|
|
| Exercise of common share options |
|
$ 42
|
(28)
|
|
|
|
|
14
|
|
| Exercise of common share options (in shares) |
|
18,189
|
|
|
|
|
|
|
|
| Share-based compensation (note 16) |
|
|
224
|
|
|
|
|
224
|
|
| Net and comprehensive loss for the period |
|
|
|
(83,692)
|
2,453
|
|
|
(81,239)
|
|
| Ending balance at Jun. 30, 2026 |
|
$ 146,609
|
$ 18,586
|
$ (454,456)
|
$ (3,365)
|
|
|
$ (292,626)
|
|
| Ending balance (in shares) at Jun. 30, 2026 |
|
13,324,608
|
|
|
|
|
|
13,324,608
|
|
|
|